We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




DxS and AstraZeneca Collaborate on Companion Diagnostic for Gefitinib

By LabMedica International staff writers
Posted on 03 Aug 2009
Print article
DxS Ltd (Manchester, UK), a personalized medicine company involved in the provision of companion diagnostics, is collaborating with AstraZeneca (Wilmington, DE; USA) a pharmaceutical company, on a companion diagnostic for use with gefitinib (iressa), AstraZeneca's treatment for nonsmall cell lung cancer (NSCLC).

DxS' clinical diagnostic, the TheraScreen: EGFR29 mutation kit will be used to test the mutation status of NSCLC patients' EGFR oncogene to identify their eligibility for treatment with iressa. The TheraScreen: EGFR29 mutation kit is based on DxS' Scorpions--a real-time polymerase chain reaction (RT-PCR)--and the Amplification Refractory Mutation System (ARMS). The kit detects low levels of a mutant in a background of wild type genomic DNA in a tumor. Results of this sensitive test are available in less than three hours.

Gefitinib has been authorized in the European Union (EU) for treatment of adults with locally advanced or metastatic NSCLC with activating mutations of epidermal growth factor receptor-tyrosine kinase (EGFR-TK), across all lines of therapy. The EU authorization is based on two phase III studies, Iressa Pan-ASia Study (IPASS) and Iressa nonsmall-cell lung cancer Trial Evaluating REsponse and Survival against Taxotere (INTEREST).

Gefitinib inhibits the tyrosine kinase enzyme in the EGFR, blocking the transmission of signals involved in the growth and spread of tumors. In approximately 10% to 15% of NSCLC cases in Caucasians, a mutation in the EGFR pathway causes tumors to be particularly susceptible to treatment with gefitinib, indicating the importance of the companion diagnostic for identifying those most suitable for treatment.

Dr Stephen Little, CEO of DxS said, "We hope that through the better understanding of the relationship between EGFR mutation status and response to anti-EGFR therapies such as iressa, patients receive the best possible cancer treatment."

Related Links:
DxS Ltd
AstraZeneca

New
Gold Member
C-Reactive Protein Reagent
CRP Ultra Wide Range Reagent Kit
Automated Blood Typing System
IH-500 NEXT
New
Human Insulin CLIA
Human Insulin CLIA Kit
New
Malaria Rapid Test
OnSite Malaria Pf/Pan Ag Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.